Posts Tagged ‘immunotherapy’
Study Finds New Therapy Effective for Common, Advanced Bladder Cancer
Following standard chemotherapy, Avelumab was found to increase the overall survival of patients with advanced urothelial bladder cancer. According to the North American Association of Central Cancer Registries, more than 80,000 Americans will be diagnosed with bladder cancer in 2022 with an anticipated loss of 17,000 patients to the disease. Most of these cases are…
Read MoreBladder Cancer Discovery: Immunotherapy as Maintenance Treatment
Bladder cancer is the sixth most common cancer in the United States. Bladder cancer is usually diagnosed at “superficial” or non-invasive stages, when it only involves the lining of the bladder and can be treated with removal of the cancerous tissue alone. However, some patients develop high-risk tumors that are likely to come back and…
Read MoreResearch Breakthroughs: Advances in Breast Cancer Diagnosis & Treatment
Mary J. Wilkinson, MD, is a medical oncologist. She is board- certified in medical oncology, internal medicine and hematology and has a special interest in breast cancer. A breast cancer diagnosis is always unwelcome news, but new advances in detection and treatment are leading to improvements in cancer care and quality of life. Here are…
Read MoreFrom Research to Results: Advances in Genitourinary Cancer Treatment
Jeanny B. Aragon-Ching, MD, is the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute. She is board certified in medical oncology, hematology and internal medicine and has a special interest in caring for patients with prostate, bladder, kidney and testicular cancers. Read Dr. Aragon-Ching’s profile. This February, I’ll be traveling to…
Read MoreNew Findings in Cancer Immunotherapy: Inova Experts Weigh In
Sekwon Jang, MD, is board certified in medical oncology, hematology and internal medicine. He serves as Inova’s director of Melanoma and Cutaneous Oncology Therapeutics and Research and director of quality at the Inova Schar Cancer Institute. He has a special interest in melanoma and other skin cancers. Read Dr. Jang’s profile. Thomas P. Conrads, PhD, recently…
Read MoreYervoy®: A New Option for Patients with Stage III Melanoma after Surgery
Sekwon Jang, MD, is board certified in internal medicine, hematology and medical oncology. He specializes in managing melanoma and other skin cancers. Dr. Jang is the director of Melanoma and Cutaneous Oncology Therapeutics and Research at the Inova Dwight and Martha Schar Cancer Institute. Read Dr. Jang’s profile. Patients with stage III melanoma (when the cancer has spread…
Read MoreImmunotherapies Offer New Hope for Melanoma Patients
Sekwon Jang, MD, is board certified in internal medicine, hematology and medical oncology. He specializes in managing melanoma and other skin cancers. Dr. Jang is the director of Melanoma and Cutaneous Oncology Therapeutics and Research at the Inova Dwight and Martha Schar Cancer Institute. Read Dr. Jang’s profile. As recently as five years ago, there…
Read More